Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Diabetologia · 2023-10 · 66 (10) · 1820-1831
DOI: 10.1007/s00125-023-05973-w ↗At a glance
Übersichtsarbeit in Diabetologia, published online on 2023-08-05. Written by Anna Solini and 2 co-authors. Institution: Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy. Major MEDLINE topics: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Cited 33 times so far (Crossref); 96 references. The full text is freely available (open access, CC BY 4.0). Funded by: Università di Pisa.
Topics: Diabetes mellitus
Abstract (original language)
Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and non-glycaemic effects, including improved insulin secretion and action, body-weight loss, blood-pressure lowering and improved lipid profile, as well as via direct effects on the heart and vasculature. These actions are likely combined with anti-inflammatory and antioxidant properties that translate into robust and consistent reductions in atherothrombotic events, particularly in people with type 2 diabetes and established atherosclerotic CVD. GLP-1RAs may also have an impact on obesity and chronic kidney disease, conditions for which cardiovascular risk-reducing options are limited. The available evidence has prompted professional and medical societies to recommend GLP-1RAs for mitigation of the cardiovascular risk in people with type 2 diabetes. This review summarises the clinical evidence for cardiovascular protection with use of GLP-1RAs and the main mechanisms underlying this effect. Moreover, it looks into how the availability of upcoming dual and triple incretin receptor agonists might expand the possibility for cardiovascular protection in people with type 2 diabetes. Graphical Abstract
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. stefano.delprato@unipi.it.
- Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy. stefano.delprato@unipi.it.
Funding
- Università di Pisa
Cite
APA
Solini, A., Tricò, D., & Del Prato, S. (2023). Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia, 66(10), 1820-1831. https://doi.org/10.1007/s00125-023-05973-w
Vancouver
Solini A, Tricò D, Del Prato S. Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia. 2023;66(10):1820-1831. doi:10.1007/s00125-023-05973-w
BibTeX
@article{Solini2023,
author = {Solini, Anna and Tricò, Domenico and Del Prato, Stefano},
title = {Incretins and cardiovascular disease: to the heart of type 2 diabetes?},
journal = {Diabetologia},
year = {2023},
volume = {66},
number = {10},
pages = {1820--1831},
doi = {10.1007/s00125-023-05973-w}
}
EUVIMED